Retrovirus vectors

The retroviral vector design with a 5' LTR and intron structure enhances vector titer and safety by reducing subgenomic RNA production and minimizing insertional mutagenesis, achieving efficient and safer gene therapy applications.

JP2026517807APending Publication Date: 2026-06-02UCL BUSINESS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
UCL BUSINESS LTD
Filing Date
2024-05-03
Publication Date
2026-06-02

Smart Images

  • Figure 2026517807000005
    Figure 2026517807000005
  • Figure 2026517807000006
    Figure 2026517807000006
  • Figure 2026517807000007
    Figure 2026517807000007
Patent Text Reader

Abstract

The present invention relates to a novel retroviral vector comprising a 5' long terminal repeat (LTR), a primer binding site, a heterologous intron, an transgene insertion site, and a 3' LTR, wherein the heterologous intron is located immediately downstream of the 5' LTR. Such a vector has a high titer production rate and is particularly suitable for gene therapy.
Need to check novelty before this filing date? Find Prior Art